Trial ID or NCT#

NCT01454687

Status

NOT RECRUITING

Purpose

The term epidermolysis bullosa (EB) is used to describe a group of genetic skin diseases associated with skin weakness, blisters, and chronic wounds. "Revertant mosaicism" means that there are two genetically different populations of cells due to spontaneous mutations. Some EB patients have normal, non-fragile skin patches which may be areas of revertant mosaicism. In the revertant areas, the proteins function normally, like non-EB skin. In this study, we plan to culture cells from the revertant areas and graft them on to the wounded areas.

Official Title

Grafting of Epidermolysis Bullosa Wounds Using Cultured Revertant Autologous Keratinocytes

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

M. Peter Marinkovich, MD
Dermatologist, Blistering disease specialist, Psoriasis specialist
Associate Professor of Dermatology
Phuong Khuu
Dermatologist, Pediatric dermatologist
Clinical Assistant Professor, Dermatology

Contact us to find out if this trial is right for you.

CONTACT

Emily S Gorell, MS
(650) 721-7166